High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
Zander
A R
AR
Krüger
W
W
Kröger
N
N
Damon
L
L
Königmann
M
M
Berdel
W E
WE
Gieseking
F
F
Schäfer-Eckart
K
K
Möbus
V
V
Frickhofen
N
N
Wandt
H
H
Illiger
H J
HJ
Metzner
B
B
Kolbe
K
K
Wörmann
B
B
Trümper
L
L
Huber
C
C
Hossfeld
D K
DK
Maass
H
H
Jonat
W
W
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005858:Germany; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009367:Neoplasm Staging; D013852:Thiotepa / Q000008:administration & dosage / Q000009:adverse effects; D014182:Transplantation, Autologous
D003520:Cyclophosphamide; D013852:Thiotepa; D008942:Mitoxantrone